世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

MEAがん免疫療法市場-2034年までの産業動向と予測


MEA Cancer Immunotherapy Market - Industry Trends and Forecast to 2034

中東・アフリカのがん免疫療法市場は、2023年の10億2,798万米ドルから2031年には18億2,508万米ドルに達し、2024年から2031年の予測期間中に年平均成長率8.3％で成長すると予測される。 市場セグメンテーション ... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年12月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		292 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

中東・アフリカのがん免疫療法市場は、2023年の10億2,798万米ドルから2031年には18億2,508万米ドルに達し、2024年から2031年の予測期間中に年平均成長率8.3％で成長すると予測される。
市場セグメンテーション
中東・アフリカがん免疫療法市場：製品タイプ別（チェックポイント阻害剤、モノクローナル抗体、ワクチン、細胞療法、免疫調節剤、がん溶解性ウイルス）、用途別（肺がん、乳がん、メラノーマ、骨髄腫、前立腺がん、卵巣がん、子宮頸がん、胃がん、大腸がん、頭頸部がん、その他）、エンドユーザー（病院、オンコロジークリニック、在宅医療、その他）、剤形（静脈内投与、筋肉内投与、経口投与）、流通チャネル（直接販売、小売販売、薬局）、国（南アフリカ、サウジアラビア、U.A.E、国別（南アフリカ、サウジアラビア、アラブ首長国連邦、エジプト、その他の中東・アフリカ地域） - 2031年までの産業動向と予測

中東およびアフリカのがん免疫療法市場ダイナミクスの概要

推進要因
- がん罹患率の上昇

抑制要因

- 免疫関連の有害事象の増加

機会

- 併用療法への傾向の高まり

市場プレイヤー

中東・アフリカのがん免疫療法市場で事業を展開する主な市場参入企業は以下の通りである：

- メルク社
- F.ホフマン・ラ・ロシュ社
- ブリストル・マイヤーズ スクイブ社
- ヤンセンファーマ
- アストラゼネカ
- ギリアド・サイエンシズ
- イーライリリー・アンド・カンパニー
- アムジェン社
- ノバルティスAG
- GSK
- ファイザー
- インサイト


ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 MIDDLE EAST AND AFRICA 177
12.1.1 SOUTH AFRICA 185
12.1.2 SAUDI ARABIA 193
12.1.3 U.A.E. 201
12.1.4 EGYPT 209
12.1.5 ISRAEL 217
12.1.6 OMAN 225
12.1.7 QATAR 233
12.1.8 BAHRAIN 241
12.1.9 REST OF MIDDLE EAST AND AFRICA 249
13 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 250
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 250
14 SWOT ANALYSIS 251
15 COMPANY PROFILES 252
15.1 MERCK & CO., INC. 252
15.1.1 COMPANY SNAPSHOT 252
15.1.2 REVENUE ANALYSIS 252
15.1.3 COMPANY SHARE ANALYSIS 253
15.1.4 PRODUCT PORTFOLIO 253
15.1.5 RECENT DEVELOPMENTS 253
15.2 F. HOFFMANN-LA ROCHE LTD 254
15.2.1 COMPANY SNAPSHOT 254
15.2.2 REVENUE ANALYSIS 254
15.2.3 COMPANY SHARE ANALYSIS 255
15.2.4 PRODUCT PORTFOLIO 255
15.2.5 RECENT DEVELOPMENTS 255
15.3 BRISTOL-MYERS SQUIBB COMPANY 257
15.3.1 COMPANY SNAPSHOT 257
15.3.2 REVENUE ANALYSIS 257
15.3.3 COMPANY SHARE ANALYSIS 258
15.3.4 PRODUCT PORTFOLIO 258
15.3.5 RECENT DEVELOPMENTS 259
15.4 JANSSEN MIDDLE EAST AND AFRICA SERVICES, LLC 260
15.4.1 COMPANY SNAPSHOT 260
15.4.2 REVENUE ANALYSIS 260
15.4.3 COMPANY SHARE ANALYSIS 261
15.4.4 PRODUCT PORTFOLIO 261
15.4.5 RECENT DEVELOPMENTS 262
15.5 ASTRAZENECA 263
15.5.1 COMPANY SNAPSHOT 263
15.5.2 REVENUE ANALYSIS 263
15.5.3 COMPANY SHARE ANALYSIS 264
15.5.4 PRODUCT PORTFOLIO 264
15.5.5 RECENT DEVELOPMENTS 265
15.6 ABBVIE INC. 266
15.6.1 COMPANY SNAPSHOT 266
15.6.2 PIPELINE PORTFOLIO 266
15.6.3 RECENT DEVELOPMENTS 266
15.7 AMGEN INC. 267
15.7.1 COMPANY SNAPSHOT 267
15.7.2 REVENUE ANALYSIS 268
15.7.3 PIPELINE PORTFOLIO 268
15.7.4 PRODUCT PORTFOLIO 269
15.7.5 RECENT DEVELOPMENTS 269
15.8 ATARA BIOTHERAPEUTICS, INC. 270
15.8.1 COMPANY SNAPSHOT 270
15.8.2 PIPELINE PORTFOLIO 270
15.8.3 RECENT DEVELOPMENTS 270
15.9 BAYER AG 271
15.9.1 COMPANY SNAPSHOT 271
15.9.2 PIPELINE PORTFOLIO 271
15.9.3 RECENT DEVELOPMENTS 271
15.10 CELLDEX THERAPEUTICS. 273
15.10.1 COMPANY SNAPSHOT 273
15.10.2 PIPELINE PORTFOLIO 273
15.10.3 RECENT DEVELOPMENTS 273
15.11 CELLECTIS 274
15.11.1 COMPANY SNAPSHOT 274
15.11.2 PIPELINE PORTFOLIO 274
15.11.3 RECENT DEVELOPMENTS 274
15.12 GILEAD SCIENCES, INC. 275
15.12.1 COMPANY SNAPSHOT 275
15.12.2 REVENUE ANALYSIS 275
15.12.3 PRODUCT PORTFOLIO 276
15.12.4 RECENT DEVELOPMENTS 276
15.13 GSK PLC. 277
15.13.1 COMPANY SNAPSHOT 277
15.13.2 REVENUE ANALYSIS 277
15.13.3 PRODUCT PORTFOLIO 278
15.13.4 RECENT DEVELOPMENTS 278
15.14 INCYTE. 279
15.14.1 COMPANY SNAPSHOT 279
15.14.2 REVENUE ANALYSIS 279
15.14.3 PRODUCT PORTFOLIO 280
15.14.4 RECENT DEVELOPMENTS 280
15.15 LILLY. 281
15.15.1 COMPANY SNAPSHOT 281
15.15.2 REVENUE ANALYSIS 282
15.15.3 PRODUCT PORTFOLIO 282
15.15.4 RECENT DEVELOPMENTS 283
15.16 NOVARTIS AG 284
15.16.1 COMPANY SNAPSHOT 284
15.16.2 REVENUE ANALYSIS 284
15.16.3 PIPELINE PORTFOLIO 285
15.16.4 PRODUCT PORTFOLIO 285
15.16.5 RECENT DEVELOPMENTS 285
15.17 PFIZER INC. 286
15.17.1 COMPANY SNAPSHOT 286
15.17.2 REVENUE ANALYSIS 286
15.17.3 PRODUCT PORTFOLIO 287
15.17.4 RECENT DEVELOPMENTS 287
16 QUESTIONNAIRE 288
17 RELATED REPORTS 292

　

ページTOPに戻る


　

Summary

The Middle East and Africa cancer immunotherapy market is expected to reach USD 1,825.08 million by 2031 from USD 1,027.98 million in 2023, growing at a CAGR of 8.3% during the forecast period of 2024 to 2031.
Market Segmentation
Middle East and Africa Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Middle East and Africa Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restraint

• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Middle East and Africa cancer immunotherapy market are:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 MIDDLE EAST AND AFRICA 177
12.1.1 SOUTH AFRICA 185
12.1.2 SAUDI ARABIA 193
12.1.3 U.A.E. 201
12.1.4 EGYPT 209
12.1.5 ISRAEL 217
12.1.6 OMAN 225
12.1.7 QATAR 233
12.1.8 BAHRAIN 241
12.1.9 REST OF MIDDLE EAST AND AFRICA 249
13 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 250
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 250
14 SWOT ANALYSIS 251
15 COMPANY PROFILES 252
15.1 MERCK & CO., INC. 252
15.1.1 COMPANY SNAPSHOT 252
15.1.2 REVENUE ANALYSIS 252
15.1.3 COMPANY SHARE ANALYSIS 253
15.1.4 PRODUCT PORTFOLIO 253
15.1.5 RECENT DEVELOPMENTS 253
15.2 F. HOFFMANN-LA ROCHE LTD 254
15.2.1 COMPANY SNAPSHOT 254
15.2.2 REVENUE ANALYSIS 254
15.2.3 COMPANY SHARE ANALYSIS 255
15.2.4 PRODUCT PORTFOLIO 255
15.2.5 RECENT DEVELOPMENTS 255
15.3 BRISTOL-MYERS SQUIBB COMPANY 257
15.3.1 COMPANY SNAPSHOT 257
15.3.2 REVENUE ANALYSIS 257
15.3.3 COMPANY SHARE ANALYSIS 258
15.3.4 PRODUCT PORTFOLIO 258
15.3.5 RECENT DEVELOPMENTS 259
15.4 JANSSEN MIDDLE EAST AND AFRICA SERVICES, LLC 260
15.4.1 COMPANY SNAPSHOT 260
15.4.2 REVENUE ANALYSIS 260
15.4.3 COMPANY SHARE ANALYSIS 261
15.4.4 PRODUCT PORTFOLIO 261
15.4.5 RECENT DEVELOPMENTS 262
15.5 ASTRAZENECA 263
15.5.1 COMPANY SNAPSHOT 263
15.5.2 REVENUE ANALYSIS 263
15.5.3 COMPANY SHARE ANALYSIS 264
15.5.4 PRODUCT PORTFOLIO 264
15.5.5 RECENT DEVELOPMENTS 265
15.6 ABBVIE INC. 266
15.6.1 COMPANY SNAPSHOT 266
15.6.2 PIPELINE PORTFOLIO 266
15.6.3 RECENT DEVELOPMENTS 266
15.7 AMGEN INC. 267
15.7.1 COMPANY SNAPSHOT 267
15.7.2 REVENUE ANALYSIS 268
15.7.3 PIPELINE PORTFOLIO 268
15.7.4 PRODUCT PORTFOLIO 269
15.7.5 RECENT DEVELOPMENTS 269
15.8 ATARA BIOTHERAPEUTICS, INC. 270
15.8.1 COMPANY SNAPSHOT 270
15.8.2 PIPELINE PORTFOLIO 270
15.8.3 RECENT DEVELOPMENTS 270
15.9 BAYER AG 271
15.9.1 COMPANY SNAPSHOT 271
15.9.2 PIPELINE PORTFOLIO 271
15.9.3 RECENT DEVELOPMENTS 271
15.10 CELLDEX THERAPEUTICS. 273
15.10.1 COMPANY SNAPSHOT 273
15.10.2 PIPELINE PORTFOLIO 273
15.10.3 RECENT DEVELOPMENTS 273
15.11 CELLECTIS 274
15.11.1 COMPANY SNAPSHOT 274
15.11.2 PIPELINE PORTFOLIO 274
15.11.3 RECENT DEVELOPMENTS 274
15.12 GILEAD SCIENCES, INC. 275
15.12.1 COMPANY SNAPSHOT 275
15.12.2 REVENUE ANALYSIS 275
15.12.3 PRODUCT PORTFOLIO 276
15.12.4 RECENT DEVELOPMENTS 276
15.13 GSK PLC. 277
15.13.1 COMPANY SNAPSHOT 277
15.13.2 REVENUE ANALYSIS 277
15.13.3 PRODUCT PORTFOLIO 278
15.13.4 RECENT DEVELOPMENTS 278
15.14 INCYTE. 279
15.14.1 COMPANY SNAPSHOT 279
15.14.2 REVENUE ANALYSIS 279
15.14.3 PRODUCT PORTFOLIO 280
15.14.4 RECENT DEVELOPMENTS 280
15.15 LILLY. 281
15.15.1 COMPANY SNAPSHOT 281
15.15.2 REVENUE ANALYSIS 282
15.15.3 PRODUCT PORTFOLIO 282
15.15.4 RECENT DEVELOPMENTS 283
15.16 NOVARTIS AG 284
15.16.1 COMPANY SNAPSHOT 284
15.16.2 REVENUE ANALYSIS 284
15.16.3 PIPELINE PORTFOLIO 285
15.16.4 PRODUCT PORTFOLIO 285
15.16.5 RECENT DEVELOPMENTS 285
15.17 PFIZER INC. 286
15.17.1 COMPANY SNAPSHOT 286
15.17.2 REVENUE ANALYSIS 286
15.17.3 PRODUCT PORTFOLIO 287
15.17.4 RECENT DEVELOPMENTS 287
16 QUESTIONNAIRE 288
17 RELATED REPORTS 292

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（電池）の最新刊レポート

Data Bridge Market Research 社の最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/10/04　10:27

147.72 円

163.39 円

196.69 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.